Eli Lilly: positive post-hoc analysis for Emgality

(CercleFinance.com) - Eli Lilly has announced that a post-hoc analysis demonstrated the efficacy of its Emgality (galcanezumab-gnlm) in patients suffering from episodic and chronic migraine, for whom preventive treatment with BOTOX has failed.


Detailed results from a post-hoc analysis of three Phase 3 studies (EVOLVE-1, EVOLVE-2 and REGAIN) will be presented as a late-breaking presentation on Saturday 30 June at the American Headache Society (AHS) annual meeting in San Fransico.

Eli Lilly adds that the brand name of this product has been conditionally approved by the FDA. The latter is currently studying the file for authorization in the prevention of migraine in adults, with a decision expected by the end of September.


Copyright (c) 2018 CercleFinance.com. All rights reserved.